{"filing":{"accession_number":"0000879169-26-000048","cik":"0000879169","ticker":"INCY","company_name":"INCYTE CORP","form":"8-K","filing_date":"2026-07-06","report_date":null,"primary_document":"incy-20260706.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/879169/000087916926000048/incy-20260706.htm"},"events":[{"id":17021,"run_id":15240,"accession_number":"0000879169-26-000048","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"Incyte announced completion of its acquisition of Vega Therapeutics for $1.25 billion upfront plus up to $750 million in sales milestone payments. The acquisition adds VGA039, a Phase 3 monoclonal antibody for von Willebrand disease, to Incyte's hematology portfolio. This is a material M\u0026A transaction involving a substantial cash outlay and a late-stage clinical asset that strengthens the company's pipeline.","company_name":"INCYTE CORP","ticker":"INCY","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":15313,"accession_number":"0000879169-26-000048","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Incyte announced completion of its acquisition of Vega Therapeutics for $1.25 billion upfront plus up to $750 million in sales milestone payments. The acquisition adds VGA039, a Phase 3 monoclonal antibody for von Willebrand disease, to Incyte's hematology portfolio. This is a material M\u0026A transaction involving a substantial cash outlay and a late-stage clinical asset that strengthens the company's pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:45:32.331192+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15313,"accession_number":"0000879169-26-000048","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Incyte announced completion of its acquisition of Vega Therapeutics for $1.25 billion upfront plus up to $750 million in sales milestone payments. The acquisition adds VGA039, a Phase 3 monoclonal antibody for von Willebrand disease, to Incyte's hematology portfolio. This is a material M\u0026A transaction involving a substantial cash outlay and a late-stage clinical asset that strengthens the company's pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:45:32.331192+00:00","company_name":"INCYTE CORP","ticker":"INCY","filing_date":"2026-07-06"}]}